

Innovation Type and Reference Number; 5.33

Title of Innovation; Antibacterial Prescribing in Cardiff and the Vale of Glamorgan

Contact; Karen May; Karen.May2@wales.nhs.uk

Project Aim; Reduce harm, waste and variation in antibacterial prescribing in Primary Care

Strategic Theme; Promoting Cultural Change; Primary Care Support

Component of new Primary Care Model; Cultural change, prevention and risk stratification to reduce demand on PC & Acute Care

Objectives / Value within whole system model for PC in Wales;

Early Outcomes; Quinolone prescribing decreased by approx. 9% across Wales and 14.4% in CAV (measured as items per 1000 patients). Co-amoxiclav prescribing reduced by approximately 18% across Wales and 32% in CAV, more than any other HB (measured as items per 1000 patients).

Summary of First Evaluation; In the year to March 2016 antibacterial usage fell by 6% in Wales. CAV saw the largest % decrease (8.53%). Cephalosporin prescribing in CAV decreased to the lowest in Wales. Items per 1000 patients decreased by 27.6%. CAV is now lower than the English average for this indicator.

Updated Outcome Findings; Improvement in antibacterial prescribing performance in national prescribing indicators

Antibacterial performance continues to be good compared to wales average – ongoing process to continually promote messages. Access to primary care micro-guide from GP computers arranged

Antibacterial prescribing is a priority from an antibacterial resistance perspective.

Antibacterial prescribing is included in the Medicines Management Incentive Scheme.

It is a key focus of National Prescribing Indicator performance, RCA of C Diff occurrences, retrospective review of prescribing and comparison to guidance.

Antibacterial prescribing is discussed at the annual prescribing meeting with the prescribing advisor.

Status / Additional Comments; NPI performance shows that C&V are regularly in the top quartile in Wales for antibacterial prescribing.

The NPIs have changed, they now combine to include the 4C anti-bacterial agents, instead of one indicator for each – this is likely to be fairer on practices and less likely to be adversely affected by small movements in one antibacterial.

Evaluation; Ongoing – evaluation is by quarterly NPI performance. Aims to deliver antibiotic awareness campaign in November 18 with a roll out and promotion of new UTI guidance